The recent improvement in diagnostic tools accuracy as well as the availability of new therapeutic strategies against several viral and not viral-related liver diseases have led to significant changes in clinical practice. Moreover, cirrhosis-related complications still remain strong predictors of prognosis, also in those patients achieving a virological response to current anti-HCV and anti-HBV therapies. Therefore, several efforts have been recently made in order to optimize both the diagnostic and therapeutic algorithms of patients affected by HCC and portal hypertension. Finally, we face with growing interest in chronic liver diseases due to changes in epidemiology (i.e. HDV infection, NASH and ASH) and/or availability of new therapeutic compounds (i.e. HDV, NASH, PBC).

The “Hepatitis Masterclass 2019” will represent a unique opportunity to face with novelties in specific Hepatology fields and to discuss with International experts on the impact of new diagnostic and therapeutic strategies in field practice.